secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2025-08-14T23:59:59+00:00
Accession:  0000950170-25-108846
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Clearside receives Nasdaq delisting notice; Chairperson Gibney resigns, Thorp succeeds
--------------------------------------------------------------------------------

- Nasdaq notified Clearside on Aug 11, 2025 that its common stock is subject to delisting due to bid price below $1.00 for 30 consecutive business days.
- Clearside intends to request a hearing before Nasdaq Panel to stay delisting; stock will continue trading pending hearing process.
- Company is seeking stockholder approval for a reverse stock split at ratio 1-for-5 to 1-for-15 to regain minimum bid price compliance.
- Anthony Gibney resigned as Chairperson and board member effective Aug 11, 2025; appointed CFO of Aura Biosciences; no dispute.
- Board appointed existing member Clay B. Thorp as new Chairperson effective Aug 13, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025108846/0000950170-25-108846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017025108846/clsd-20250814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-108846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer